Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Rennes – page 50

865 clinical trials in Rennes, France across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Rennes at a glance
865
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

865 trials in Rennes

Open in trial search

Neuroendocrine carcinoma of the skin+9

Not recruiting

Study on Reduced Dose Intensity of Pembrolizumab and Drug Combination for Patients with Advanced or Metastatic Cancer Responding to Standard Immunotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Unicancer

Haemophagocytic lymphohistiocytosis

Not recruiting

Study on Itacitinib for Treating Non-Severe Hemophagocytic Lymphohistiocytosis in Adults

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Itacitinib
  • Sponsor:Assistance Publique Hopitaux De Paris

Systemic scleroderma

Not recruiting

Study on Itacitinib for Adults with Diffuse Systemic Sclerosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Itacitinib
  • Sponsor:Assistance Publique Hopitaux De Paris

Colorectal cancer metastatic

Not recruiting

Study of Pembrolizumab with Drug Combination for Patients with Microsatellite Stable Metastatic Colorectal Cancer with High Immune Infiltrate

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondation Franc.Cancerologie Digestive

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

B-cell lymphoma recurrent+1

Not recruiting

Study on the Safety and Effectiveness of Glofitamab and Obinutuzumab for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:F. Hoffmann-La Roche AG

Paresis

Not recruiting

Study on the Effectiveness and Safety of NT 201 (Botulinum Toxin) for Treating Lower Limb Spasticity in Adults After Stroke or Traumatic Brain Injury

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
  • Sponsor:Merz Pharmaceuticals GmbH

Acute kidney injury

Not recruiting

Study on TIN816 for Preventing Acute Kidney Injury in Adults Undergoing Cardiac Surgery

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tin816
  • Sponsor:Novartis Pharma AG

Acute myeloid leukaemia

Not recruiting

Study on Gemtuzumab Ozogamicin and Gilteritinib for Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Centre Antoine Lacassagne

Peripheral T-cell lymphoma unspecified

Not recruiting

Study of Lacutamab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:LYSARC

Delirium

Not recruiting

Study on the Effects of Isoflurane and Propofol on Delirium in Intensive Care Patients on Mechanical Ventilation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Isoflurane
  • Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Asplenia

Not recruiting

Study on the Safety and Immune Response of Meningococcal B Vaccines in Adults with Asplenia: Bexsero, Trumenba, and a Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Neisseria Meningitidis Group B Fhbp Protein Subfamily A
  • Sponsor:Assistance Publique Hopitaux De Paris

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Rennes

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on head and neck cancers, breast cancer, and hematologic malignancies. Studies are evaluating novel therapeutic approaches including immunotherapy combinations and targeted treatments.

  • Advanced squamous cell carcinoma treatments
  • Triple-negative breast cancer interventions
  • Acute myeloid leukemia therapies

Multiple research centers are investigating breakthrough treatments for various stages of cancer progression.

02 Neurological Disorders

Comprehensive research into multiple sclerosis and movement disorders, utilizing advanced imaging techniques and innovative therapeutic approaches.

  • MS treatment optimization
  • Essential tremor management
  • Neuroinflammation imaging

Studies are focused on improving patient outcomes through targeted interventions and precision medicine approaches.

03 Critical Care Medicine

Investigating new approaches in postoperative care and immunotherapy for critical care patients, with emphasis on patient comfort and infection prevention.

  • Pain management protocols
  • Immune system modulation
  • Post-surgical care optimization

Research aims to enhance recovery outcomes and reduce complications in intensive care settings.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.